<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">334</article-id><article-id pub-id-type="doi">10.15690/vramn.v67i3.187</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SHORT MESSAGES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">THE INFLUENCE OF POINT MUTATIONS IN THE EPSTEIN-BARR VIRUS LMP1 ONCOGENE ON THE CELL CYTOSKELETON AND ACTIVATION OF INDUCIBLE FORM OF NO SYNTHASE</article-title><trans-title-group xml:lang="ru"><trans-title>ВЛИЯНИЕ ТОЧЕЧНЫХ МУТАЦИЙ В БЕЛКЕ LMP1 ВИРУСА ЭПШТЕЙНА−БАРР НА ЦИТОСКЕЛЕТ КЛЕТКИ И АКТИВАЦИЮ ИНДУЦИБЕЛЬНОЙ ФОРМЫ NO-СИНТАЗЫ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Diduk</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Дидук</surname><given-names>С. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>кандидат биологических наук, научный сотрудник лаборатории вирусного канцерогенеза НИИ канцерогенеза Российского онкологического научного центра имени Н.Н. Блохина РАМН Адрес: 115478, Москва, Каширское шоссе, д. 24 Тел.: (495) 323-57-55, факс: (495) 324-12-05</p></bio><email>diduksv@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Smirnova</surname><given-names>K. V.</given-names></name><name xml:lang="ru"><surname>Смирнова</surname><given-names>К. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>кандидат биологических наук, научный сотрудник лаборатории вирусного канцероге- неза НИИ канцерогенеза Российского онкологического научного центра имени Н.Н. Блохина РАМН Адрес: 115478, Москва, Каширское шоссе, д. 24</p></bio><email>smirnovakv@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gurtsevitch</surname><given-names>V. E.</given-names></name><name xml:lang="ru"><surname>Гурцевич</surname><given-names>В. Э.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий лабораторией вирусного канце- рогенеза НИИ канцерогенеза Российского онкологического научного центра имени Н.Н. Блохина РАМН Адрес: 115478, Москва, Каширское шоссе, д. 24 Тел.: (495) 324-25-64</p></bio><email>gurtsevitch@yahoo.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin Russian Cancer Research Center RAMS</institution></aff><aff><institution xml:lang="ru">ФГБУ Российский онкологический научный центр имени Н.Н. Блохина РАМН, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-03-23" publication-format="electronic"><day>23</day><month>03</month><year>2012</year></pub-date><volume>67</volume><issue>3</issue><issue-title xml:lang="en">Vestnik Rossiiskoi akademii medetsinskikh nauk / Annals of the Russian academy of medical sciences</issue-title><issue-title xml:lang="ru">Вестник Российской академии медицинских наук</issue-title><fpage>62</fpage><lpage>67</lpage><history><date date-type="received" iso-8601-date="2015-08-07"><day>07</day><month>08</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, Издательство "Педиатръ"</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/334">https://vestnikramn.spr-journal.ru/jour/article/view/334</self-uri><abstract xml:lang="en"><p><italic>One of the latent proteins encoded by the Epstein−Barr virus (EBV), the latent membrane protein 1 (LMP1), plays a key role in developing of EBV-associated human malignancies. Polymorphism of LMP1 protein is its characteristic feature. Some specific mutations in LMP1 genome have previously been detected in different geographic regions, however, the influence of these mutations on functional activity of LMP1 was not still determined. I</italic><italic>n this study we demonstrated for the first time the significance of individual point mutations among common ones observed in LMP1 and their combination on activation of the inducible form of nitric oxide synthase (</italic><italic>iNOS)</italic><italic>. In addition, the influence of above mutations localized in the CTAR regions of the LMP1 molecule has also been investigated on structural components of the fibroblasts of the Rat1cell line.</italic><italic/><italic/></p><p> </p></abstract><trans-abstract xml:lang="ru"><p><italic>В состав генома вируса Эпштейна−Барр (ВЭБ) входит онкоген </italic><italic>LMP</italic><italic>1, который играет ключевую роль в развитии ВЭБ-ассоциированных патологий человека. Отличительной особенностью этого вирусного белка является его полиморфизм. Ранее в различных географических регионах планеты были выявлены характерные мутации в последовательности </italic><italic>LMP</italic><italic>1, но их влияние на функциональные свойства онкогена остается до сих пор не выясненным. В нашем исследовании впервые показано значение отдельных часто выявляемых точечных мутаций и их сочетаний в </italic><italic>LMP</italic><italic>1 в активации индуцибельной формы </italic><italic>NO</italic><italic>-синтазы. Кроме того, нами исследовано влияние этих мутаций, локализованных в CTAR-областях молекулы </italic><italic>LMP</italic><italic>1, на структурные компоненты клеток крысиных фибробластов </italic><italic>Rat</italic><italic>1. </italic></p><p> </p></trans-abstract><kwd-group xml:lang="en"><kwd>the Epstein−Barr virus</kwd><kwd>the latent membrane protein 1</kwd><kwd>iNOS</kwd><kwd>actin</kwd><kwd>paxillin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>вирус Эпштейна−Барр</kwd><kwd>белок LMP1</kwd><kwd>iNOS</kwd><kwd>актин</kwd><kwd>паксиллин</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Young L.S., Rickinson A.B. Epstein−Barr virus: 40 years on. Nat. Rev. Cancer. 2004; 4 (10): 757−768.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	Young L., Alfieri C., Hennessy K. et al. Expression of Epstein−Barr virus trasformation-associated genes in tissues of patients with EBV lymphoproliferative diseases. New Engl. J. Med. 1989; 321: 1080−1085.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.	Kaye K., Izumi K., Kieff E. Epstein−Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA. 1993; 90: 9150−9154.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.	Moorthy R.K., Thorley-Lawson D.A. All three domains of the Epstein−Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J. Virol. 1993; 67: 1638−1646.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.	Mosialos G., Birkenbach M., Yalamanchili R. et al. The Epstain−Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995; 80: 389−399.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.	Mosialos G. Cytokine signaling and Epstein−Barr virus-mediated cell transformation. Cytokine &amp; Growth Factor. 2001; 12: 259–270.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.	McFarland M.D.C., Izumi K.M., Mosialos G. Epstein−Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kB. Oncogene. 1999; 18: 6959–6964.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.	Wu L., Nakano H., Wu Z. The C-terminal activating region 2 of the Epstein−Barr virus-encoded latent membrane protein 1 activates NF-kB through TRAF6 and TAK1. J. Biol. Chem. 2006; 281 (4): 2162–2169.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.	Eliopoulos A.G., Young L.S. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein−Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene. 1998; 16: 1731−1742.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.	Eliopoulos, A.G., Blake, S.M., Floettmann, J.E. et al. Epstein−Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol. 1999; 73: 1023−1025.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.	Lam N., Sugden B. CD40 and its viral mimic, LMP1: similar means to different ends. Cell. Signal. 2003; 15: 9−16.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12.	Dawson C.W., Tramountanis G., Eliopoulos A.G., Young L.S. Epstein−Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J. Biolog. Chem. 2003; 278 (6): 3694–3704.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13.	Wakisaka N., Kondo S., Yoshizaki T. et al. Epstein−Barr virus latent membrane protein 1 induces hypoxia-inducible factor 1α. Molecular and Cellular Biol. 2004; 24 (12): 5223−5234.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14.	Yu J., Tsai H., Wu C. et al. Induction of inducible nitric oxide synthase by Epstein−Barr virus B95-8-derived LMP1 in BALB/3T3 cells promotes stress-induced cell death and impaires LMP1-mediated transformation. Oncogene. 2002; 21: 8047−8061.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15.	Chew M.M., Gan S.Y., Khoo A.S., Tan E.L. Interleukins, laminin and Epstein−Barr virus latent protein 1 (EBV LMP1) promote metastatic phenotype in nasopharyngeal carcinoma. BMC Cancer. 2010; 10: 574.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16.	Smirnova K.V., Diduk S.V., Gurtsevich V.E. Functional analysis of variants of latent membrane protein 1 (LMP1) of Epstein-Barr virus in patients with lymphoproliferative diseases. Biomeditsinskaya khimiya = Biomedical chemistry. 2010; 3: 273−284.</mixed-citation></ref></ref-list></back></article>
